Stockscreener 앱 받기
4.535
7.98%
0.335
시간 외 거래:
4.57
0.035
+0.77%
전일 마감가:
$4.20
열려 있는:
$4.58
하루 거래량:
1.95M
Relative Volume:
0.61
시가총액:
$517.07M
수익:
$884.00K
순이익/손실:
$-103.64M
주가수익비율:
-3.2523
EPS:
-1.3944
순현금흐름:
$-95.45M
1주 성능:
+4.25%
1개월 성능:
+1.91%
6개월 성능:
+42.16%
1년 성능:
+133.76%
1일 변동 폭
$4.31
$4.755
1주일 범위
$4.05
$4.755
52주 변동 폭
$1.86
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.535 | 478.87M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Piper Sandler | Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
CATX Reiterates by Wedbush -- Price Target Maintained at $11 - GuruFocus
[212Pb]VMT-α-NET Shows Promising Safety and Efficacy in Advanced Neuroendocrine Tumor Phase I/IIa Trial (Data Cutoff March 2026) - Minichart
Perspective Therapeutics (CATX) Updates Clinical Trial Results f - GuruFocus
Perspective Therapeutics reports interim trial results for NET therapy - Investing.com
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial - marketscreener.com
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - The Manila Times
[8-K] Perspective Therapeutics, Inc. Reports Material Event - Stock Titan
Early tumor trial: 43% responded, 72% stayed alive without progression - Stock Titan
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics Inc. R (AAJ0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView — Track All Markets
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - Stock Titan
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CATX Should I Buy - Intellectia AI
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.72%
자본화:
|
볼륨(24시간):